Target mediated disposition of T84.66, a monoclonal anti-CEA antibody: Application in the detection of colorectal cancer xenografts

mAbs

Volumn 2, Issue 1, 2010, Pages 67-72

  Urva, Shweta R ^a   Balthasar, Joseph P ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Anti CEA IgG; Carcinoembryonic antigen (CEA); Screening test; Sensitivity; Specificity; T84.66; Target mediated disposition (TMD)

Indexed keywords

CARCINOEMBRYONIC ANTIBODY; IODINE 125; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY T 84 66; T 88 46; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER DIAGNOSIS; CANCER MODEL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG CLEARANCE; FOLLOW UP; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; NUDE MOUSE; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; HUMANS; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN;

EID: 77953653403     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.2.1.10781     Document Type: Article

References (41)

1. American Cancer Society. Cancer facts & figures 2008. http://www.cancer.org/downloads/ STT/2008CAFFfinalsecured.pdf.
2. American Cancer Society. Colorectal cancer facts & figures 2008-2010. http://www.cancer.org/downloads/STT/F861708finalforweb.pdf.
3. Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med 1965; 122:467-81.
4. Gold P, Freedman SO. Demonstration of tumorspecific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965; 121:439-62.
5. Shively JE, Beatty JD. CEA-related antigens: molecular biology and clinical significance. Crit Rev Oncol Hematol 1985; 2:355-99.
6. Hefta LJ, Neumaier M, Shively JE. Kinetic and affinity constants of epitope specific anti-carcinoembryonic antigen (CEA) monoclonal antibodies for CEA and engineered CEA domain constructs. Immunotechnology 1998; 4:49-57.
7. Thomson DM, Krupey J, Freedman SO, Gold P. The radioimmunoassay of circulating carcinoembryonic antigen of the human digestive system. Proc Natl Acad Sci USA 1969; 64:161-7.
8. de Diego A, Compte L, Sanchis J, Enguidanos MJ, Marco V. Usefulness of carcinoembryonic antigen determination in bronchoalveolar lavage fluid. A comparative study among patients with peripheral lung cancer, pneumonia and healthy individuals. Chest 1991; 100:1060-3.
9. Amino N, Kuro R, Yabu Y, Takai SI, Kawashima M, Morimoto S, et al. Elevated levels of circulating carcinoembryonic antigen in hypothyroidism. J Clin Endocrinol Metab 1981; 52:457-62.
10. Stevens DP, Mackay IR. Increased carcinoembryonic antigen in heavy cigarette smokers. Lancet 1973; 2:1238-9.
11. Witherspoon LR, Shuler SE, Alyea K, Husserl FE. Carcinoembryonic antigen: assay following heat compared with perchloric acid extraction in patients with colon cancer, non-neoplastic gastrointestinal diseases, or chronic renal failure. J Nucl Med 1983; 24:916-21.
12. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008; 134:1570-95.
13. Yazaki PJ, Wu AM, Tsai SW, Williams LE, Ikler DN, Wong JY, et al. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. Bioconjug Chem 2001; 12:220-8.
14. Sundaresan G, Yazaki PJ, Shively JE, Finn RD, Larson SM, Raubitschek AA, et al. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003; 44:1962-9.
15. Olafsen T, Cheung CW, Yazaki PJ, Li L, Sundaresan G, Gambhir SS, et al. Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng Des Sel 2004; 17:21-7.
16. McBride WJ, Zanzonico P, Sharkey RM, Noren C, Karacay H, Rossi EA, et al. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled haptenpeptide. J Nucl Med 2006; 47:1678-88.
17. Urva SR, Yang VC, Balthasar JP. Physiologically based pharmacokinetic model for T84.66: A monoclonal anti-CEA antibody. J Pharm Sci 2009.
18. Garg A, Balthasar JP. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 2007; 34:687-709.
19. Levy G. Pharmacologic target-mediated drug disposition. Clinical pharmacology and therapeutics 1994; 56:248-52.
20. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001; 28:507-32.
21. Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, et al. Safety, pharmacokinetics and activity of ABX-EGF, a fully human antiepidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004; 22:3003-15.
22. McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 2002; 62:209-43.
23. Coffey GP, Fox JA, Pippig S, Palmieri S, Reitz B, Gonzales M, et al. Tissue distribution and receptormediated clearance of anti-CD11a antibody in mice. Drug metab dispos 2005; 33:623-9.
24. Mager DE, Mascelli MA, Kleiman NS, Fitzgerald DJ, Abernethy DR. Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. J Pharmacol Exp Ther 2003; 307:969-76.
25. Chung JK, Jang JJ, Lee DS, Lee MC, Koh CS. Tumor concentration and distribution of carcinoembryonic antigen measured by in vitro quantitative autoradiography. J Nucl Med 1994; 35:1499-505.
26. Goldenberg DM, Kim EE, DeLand FH, Bennett S, Primus FJ. Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen. Cancer Res 1980; 40:2984-92.
27. Blumenthal RD, Osorio L, Hayes MK, Horak ID, Hansen HJ, Goldenberg DM. Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft. Cancer Immunol Immunother 2005; 54:315-27.
28. Baxter LT, Zhu H, Mackensen DG, Butler WF, Jain RK. Biodistribution of monoclonal antibodies: scaleup from mouse to human using a physiologically based pharmacokinetic model. Cancer Res 1995; 55:4611-22.
29. Wong JY, Thomas GE, Yamauchi D, Williams LE, Odom-Maryon TL, Liu A, et al. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody. J Nucl Med 1997; 38:1951-9.
30. Odom-Maryon TL, Williams LE, Chai A, Lopatin G, Liu A, Wong YC, et al. Pharmacokinetic modeling and absorbed dose estimation for chimeric anti-CEA antibody in humans. J Nucl Med 1997; 38:1959-66.
31. van Osdol W, Fujimori K, Weinstein JN. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier". Cancer Res 1991; 51:4776-84.
32. Juweid M, Neumann R, Paik C, Perez-Bacete MJ, Sato J, van Osdol W, et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 1992; 52:5144-53.
33. Baxter LT, Zhu H, Mackensen DG, Jain RK. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 1994; 54:1517-28.
34. Goh V, Halligan S, Daley F, Wellsted DM, Guenther T, Bartram CI. Colorectal tumor vascularity: quantitative assessment with multidetector CT-do tumor perfusion measurements reflect angiogenesis? Radiology 2008; 249:510-7.
35. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93:2645-68.
36. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84:548-58.
37. Hammarstrom S. The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999; 9:67-81.
38. Prall F, Nollau P, Neumaier M, Haubeck HD, Drzeniek Z, Helmchen U, et al. CD66a (BGP), an adhesion molecule of the carcinoembryonic antigen family, is expressed in epithelium, endothelium and myeloid cells in a wide range of normal human tissues. J Histochem Cytochrom 1996; 44:35-41.
39. Metze D, Bhardwaj R, Amann U, Eades-Perner AM, Neumaier M, Wagener C, et al. Glycoproteins of the carcinoembryonic antigen (CEA) family are expressed in sweat and sebaceous glands of human fetal and adult skin. J Invest Dermatol 1996; 106:64-9.
40. Nap M, Hammartrom ML, Bormer O, Hammarstrom S, Wagener C, Handt S, et al. Specificity and affinity of monoclonal antibodies against carcinoembryonic antigen. Cancer Res 1992; 52:2329-39.
41. Wilkinson RW, Ross EL, Ellison D, Zimmermann W, Snary D, Mather SJ. Evaluation of a transgenic mouse model for anti-human CEA radioimmunotherapeutics. J Nucl Med 2002; 43:1368-76.